Huang Sheng, Chi Yayun, Chi Weiru, Guo Rong, Su Yonghui, Xue Jingyan, Zhou Shaoqiang, Wang Jiankui, Yang Zhuangqing, Nie Jianyun, Shao Zhimin, Chen Dedian, Wu Jiong
1Department of Breast Surgery, Key Laboratory of Breast Cancer in Shanghai, Fudan University Shanghai Cancer Center, Building 2, No. 270 Dong An Road, Shanghai, 200032 China.
2Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China.
Cancer Cell Int. 2019 Aug 7;19:210. doi: 10.1186/s12935-019-0887-x. eCollection 2019.
Long non-coding RNAs play an important role in breast cancer. Even with adjuvant hormone therapy, patients with estrogen receptor positive breast cancer can present with recurrences and distant metastases. We investigated whether the expression of a novel long non-coding RNA LINC00309 can predict the outcome of breast cancer, especially for hormone-receptor positive patients.
This retrospective study collected 290 breast cancer patients including 161 patients with hormone-positive. qPCR was performed to detect the expression of LINC00309. Kaplan-Meier and Cox risk proportion model were applied to disclose the function of LINC00309 for breast cancer prognosis.
LINC00309 high expression was an independent predictor for worse disease-free survival ( = 2.127; 95% CI 1.074-4.212; = 0.030) and associated with a shorter disease-free survival ( = 0.027), especially in hormone-positive breast cancer patients (= 0.001). Also LINC00309 high expression was associated with a shorter disease-free survival both in selective estrogen receptor modulator related hormone therapy (= 0.025) and aromatase inhibitors related hormone therapy (= 0.048). Moreover, LINC00309 was an independent predictor of worse disease-free survival in hormone-receptor positive breast cancer patients on univariate ( = 4.505; 95% CI 1.722-11.785; = 0.002) and multivariate ( = 4.159; 95% CI 1.537-11.251; = 0.005) analyses.
In breast cancer, Linc00309 is significantly associated with poor prognosis and may represent a new marker of prognosis.
长链非编码RNA在乳腺癌中发挥着重要作用。即使接受辅助激素治疗，雌激素受体阳性乳腺癌患者仍可能出现复发和远处转移。我们研究了一种新型长链非编码RNA LINC00309的表达是否能预测乳腺癌的预后，特别是对于激素受体阳性患者。
这项回顾性研究收集了290例乳腺癌患者，其中161例为激素阳性患者。采用qPCR检测LINC00309的表达。应用Kaplan-Meier法和Cox风险比例模型来揭示LINC00309对乳腺癌预后的作用。
LINC00309高表达是无病生存期较差的独立预测因素（=2.127；95%可信区间1.074 - 4.212；=0.030），且与较短的无病生存期相关（=0.027），尤其是在激素阳性乳腺癌患者中（=0.001）。此外，LINC00309高表达在选择性雌激素受体调节剂相关激素治疗（=0.025）和芳香化酶抑制剂相关激素治疗（=0.048）中均与较短的无病生存期相关。而且，在激素受体阳性乳腺癌患者中，单因素分析（=4.505；95%可信区间1.722 - 11.785；=0.002）和多因素分析（=4.159；95%可信区间1.537 - 11.251；=0.005）显示，LINC00309是无病生存期较差的独立预测因素。
在乳腺癌中，Linc00309与不良预后显著相关，可能代表一种新的预后标志物。
